Service de Médecine et de la Reproduction HFME
Bron, Rhone, 69500, France
NCT Number: NCT07477340
Pregnancies achieved through assisted reproductive technology (ART) are associated with more obstetric complications than natural pregnancies.
In pregnancies achieved through in vitro fertilization, different obstetric outcomes are observed depending on the type of embryo transfer performed and the type of endometrial preparation. Studies comparing obstetric complications according to the type of transfer performed (fresh or frozen embryo transfer) suggest an increased risk of preeclampsia, fetal macrosomia, and postpartum hemorrhage in pregnancies achieved through frozen embryo transfer.
Depending on the endometrial preparation methods used prior to frozen embryo transfer, different obstetric risks are observed. Comparisons mainly focus on stimulated cycles versus natural cycles and spontaneous pregnancies. Pregnancies achieved through frozen embryo transfer in a stimulated cycle are thought to be at greater risk of preeclampsia, fetal macrosomia, and postpartum hemorrhage than natural cycles and spontaneous pregnancies. One of the first markers of this vascular adaptation is the cranio-caudal length (CCL).
Indeed, the cranio-caudal length of embryos in the first trimester is a good reflection of embryonic growth and therefore of vascular adaptation in the first trimester of pregnancy. Differences in growth between embryos from fresh transfers, frozen transfers, and spontaneous pregnancies are visible early on, as early as the first trimester.
The hypotheses put forward to explain these differences include the secretion of relaxin by the corpus luteum, which is present in the natural cycle but not in the substituted cycle. This hormone plays a role in cardiovascular and renal adaptation to pregnancy in the first trimester. Low levels of relaxin would therefore be associated with poorer cardiorenal adaptation in the first trimester and thus with greater vascular risks in late pregnancy.
Trial opening soon.
Get Notified18 year–45 year
Female
Observational
Bron, Rhone, 69500, France
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An additionnal 5m blood sample will be taken during the current blood sample at the beginning of the pregnancy.
Time frame: Up to 19 weeks
Determine whether there is a difference in plasmatic relaxin levels in ng/ml depending on the type of transfer-fresh transfer versus TEC THS versus TEC FSH.
Contact information is provided by the study sponsor or research team.
Hospices Civils de Lyon
Other
Acronym: TEC-RELAX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738068
Female Infertility, Female Urogenital Diseases
View Trial DetailsNCT07725458
Behavior, Genital Diseases
Tampa, Florida, United States
View Trial DetailsNCT07691073
Genital Diseases, Infertility
Sabadell, Barcelona, Spain
View Trial DetailsNCT07684963
Cardiovascular Diseases, Genital Diseases
View Trial Details